Catalyst Event
Ionis Pharmaceuticals Inc (IONS) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/30/2026, 12:00:00 AM
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
Korean Translation
중증 고중성지방혈증(sHTG) 치료제 올레자르센에 대한 보충 신약 허가 신청(sNDA) 우선 심사 수락에 따른 FDA의 허가 목표일(PDUFA date)이며, 이는 광범위한 환자군을 대상으로 하는 주요 잠재적 승인으로 예정됨.
Related Recent Events
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
Q1 2026 earnings release is scheduled. Analysts forecast EPS of approximately $3.90 - $4.01 and revenue around $697.82M. Medium importance is estimated based on historical earnings volatility exceeding 5% scheduled.
4/20/2026, 12:00:00 AM